CXCR4是一种含七个跨膜结构域的G蛋白偶联受体(GPCR),是基质衍生因子-1(SDF-1/CXCL12)的特异性CXC趋化因子受体。CXCR4最初被发现的身份是HIV入侵CD4+ T细胞的共受体之一,阻断CXCR4有望成为HIV治疗的新策略。CXCR4信号通路在造血干细胞的迁移、增殖和静息及其在骨髓中的滞留中发挥重要作用,并介导B细胞CD20的上调。CXCR4在23种以上的肿瘤中高表达(包括乳腺癌、卵巢癌、黑色素瘤和前列腺癌),而在正常组织中表达极低或不表达,其表达与肿瘤的存活、生长和向高SDF-1/CXCL12表达组织(如肺、肝、骨髓)的转移密切相关。
ProSci的CXCR4多克隆抗体(货号1009)是肿瘤微环境与免疫研究领域的理想工具。该抗体以人CXCR4 isoform b氨基端14个氨基酸肽段为免疫原,经肽段亲和柱纯化,可识别人、小鼠、大鼠来源的CXCR4蛋白,并预测对牛(86%)和猪(71%)具有交叉反应性。经验证可用于Western Blot、免疫组化(IHC-P)、免疫荧光(IF)、免疫细胞化学(ICC)、流式细胞术(FC)和ELISA等多种应用,覆盖从蛋白表达检测到细胞定位分析的完整实验需求。此外,该抗体通过了独立抗体验证、siRNA敲低验证及重组蛋白检测等多重特异性验证,数据可靠,品质值得信赖。
产品信息
产品货号 | 1009 |
产品名称 | CXCR4 Antibody /欣博盛生物 |
规格 | 0.02 mg / 0.1 mg |
宿主种属 | 兔 |
克隆性 | Polyclonal |
反应种属 | 人,小鼠,大鼠 |
验证应用 | ELISA, FC, ICC, IF, IHC-P, WB |
偶联 | Unconjugated |
实验图例
图1. Western Blot Validation of CXCR4 in HeLa Cells
Loading: 15 ug of lysates per lane. Antibodies: 1009 (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
图2. Immunofluorescence Validation of CXCR4 in HeLa Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling CXCR4 with 1009 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on HeLa cells.
图3. Immunohistochemistry Validation of CXCR4 in Human Spleen
Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CXCR4 antibody (1009) at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A Goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
ProSci致力于为生命科学研究者提供高品质、经过严格验证的抗体产品,以独立抗体验证和多维度特异性检测为特色,为您的科研提供坚实可靠的数据支撑。
详情请联系ProSci中国代理商——欣博盛生物